BIOGEN INC. Notes Payable, Current
BIOGEN INC. (BIIB) had Notes Payable, Current of $0 as of 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Debt, Current
us-gaap:NotesPayableCurrent · last filed 2025-10-30
- 2025-09-30: Notes Payable, Current $0.00.
- 2025-06-30: Notes Payable, Current $0.00.
- 2025-03-31: Notes Payable, Current $1.75B.
- 2024-12-31: Notes Payable, Current $1.75B.
| Period end | Notes Payable, Current |
|---|---|
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 |
| 2025-06-30 | $0.00 10-Q · filed 2025-07-31 |
| 2025-03-31 | $1.75B 10-Q · filed 2025-05-01 |
| 2024-12-31 | $1.75B 10-Q · filed 2025-10-30 |
| 2024-09-30 | $1.75B 10-Q · filed 2024-10-30 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-01 |
| 2024-03-31 | $250.00M 10-Q · filed 2024-04-24 |
| 2023-12-31 | $150.00M 10-Q · filed 2024-10-30 |
| 2023-09-30 | $500.00M 10-Q · filed 2023-11-08 |
| 2022-12-31 | $0.00 10-Q · filed 2023-11-08 |
| 2022-09-30 | $0.00 10-Q · filed 2022-10-25 |
| 2022-06-30 | $999.80M 10-Q · filed 2022-07-20 |
| 2022-03-31 | $999.50M 10-Q · filed 2022-05-03 |
| 2021-12-31 | $999.10M 10-Q · filed 2022-10-25 |
| 2021-09-30 | $998.80M 10-Q · filed 2021-10-20 |
| 2020-12-31 | $0.00 10-Q · filed 2021-10-20 |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-21 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-22 |
| 2020-03-31 | $1.50B 10-Q · filed 2020-04-23 |
| 2019-12-31 | $1.50B 10-Q · filed 2020-10-21 |
| 2019-09-30 | $1.50B 10-Q · filed 2019-10-22 |
| 2018-12-31 | $0.00 10-Q · filed 2019-10-22 |
| 2013-03-31 | $203.32M 10-Q · filed 2013-04-25 |
| 2012-12-31 | $453.38M 10-Q · filed 2013-04-25 |
| 2012-09-30 | $453.21M 10-Q · filed 2012-10-25 |
| 2012-06-30 | $453.05M 10-Q · filed 2012-07-24 |
| 2012-03-31 | $453.36M 10-Q · filed 2012-05-01 |
| 2011-12-31 | $3.29M 10-K · filed 2013-02-05 |
| 2011-09-30 | $3.42M 10-Q · filed 2011-10-28 |
| 2011-06-30 | $131.98M 10-Q · filed 2011-07-26 |
| 2011-03-31 | $134.78M 10-Q · filed 2011-04-21 |
| 2010-12-31 | $137.15M 10-K · filed 2012-02-03 |
| 2010-09-30 | $11.30M 10-Q · filed 2010-10-26 |
| 2010-06-30 | $10.10M 10-Q · filed 2010-07-20 |
| 2010-03-31 | $19.11M 10-Q · filed 2010-04-20 |
| 2009-12-31 | $19.76M 10-K · filed 2011-02-04 |
| 2009-09-30 | $15.45M 10-Q · filed 2009-10-21 |
| 2009-06-30 | $14.70M 10-Q · filed 2009-07-17 |
| 2008-12-31 | $27.67M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |